• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

三种RNA聚合酶II羧基末端结构域激酶表现出不同的底物偏好性。

Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences.

作者信息

Ramanathan Y, Rajpara S M, Reza S M, Lees E, Shuman S, Mathews M B, Pe'ery T

机构信息

Department of Biochemistry and Molecular Biology, New Jersey Medical School, University of Medicine and Dentistry of New Jersey, Newark, New Jersey 07103, USA.

出版信息

J Biol Chem. 2001 Apr 6;276(14):10913-20. doi: 10.1074/jbc.M010975200. Epub 2001 Jan 16.

DOI:10.1074/jbc.M010975200
PMID:11278802
Abstract

CDK7, CDK8, and CDK9 are cyclin-dependent kinases (CDKs) that phosphorylate the C-terminal domain (CTD) of RNA polymerase II. They have distinct functions in transcription. Because the three CDKs target only serine 5 in the heptad repeat of model CTD substrates containing various numbers of repeats, we tested the hypothesis that the kinases differ in their ability to phosphorylate CTD heptad arrays. Our data show that the kinases display different preferences for phosphorylating individual heptads in a synthetic CTD substrate containing three heptamer repeats and specific regions of the CTD in glutathione S-transferase fusion proteins. They also exhibit differences in their ability to phosphorylate a synthetic CTD peptide that contains Ser-2-PO(4). This phosphorylated peptide is a poor substrate for CDK9 complexes. CDK8 and CDK9 complexes, bound to viral activators E1A and Tat, respectively, target only serine 5 for phosphorylation in the CTD peptides, and binding to the viral activators does not change the substrate preference of these kinases. These results imply that the display of different CTD heptads during transcription, as well as their phosphorylation state, can affect their phosphorylation by the different transcription-associated CDKs.

摘要

细胞周期蛋白依赖性激酶7(CDK7)、细胞周期蛋白依赖性激酶8(CDK8)和细胞周期蛋白依赖性激酶9(CDK9)是能够使RNA聚合酶II的C端结构域(CTD)磷酸化的细胞周期蛋白依赖性激酶(CDK)。它们在转录过程中具有不同的功能。由于这三种CDK仅作用于含有不同重复次数的模型CTD底物七肽重复序列中的丝氨酸5,我们检验了这一假说,即这些激酶在磷酸化CTD七肽阵列的能力上存在差异。我们的数据表明,在含有三个七聚体重复序列的合成CTD底物以及谷胱甘肽S-转移酶融合蛋白中CTD的特定区域内,这些激酶对单个七肽的磷酸化表现出不同的偏好。它们在磷酸化含有Ser-2-PO(4)的合成CTD肽段的能力上也存在差异。这种磷酸化肽段是CDK9复合物的不良底物。分别与病毒激活因子E1A和Tat结合的CDK8和CDK9复合物,在CTD肽段中仅作用于丝氨酸5进行磷酸化,并且与病毒激活因子的结合不会改变这些激酶的底物偏好性。这些结果表明,转录过程中不同CTD七肽的展示及其磷酸化状态可能会影响它们被不同的转录相关CDK磷酸化的情况。

相似文献

1
Three RNA polymerase II carboxyl-terminal domain kinases display distinct substrate preferences.三种RNA聚合酶II羧基末端结构域激酶表现出不同的底物偏好性。
J Biol Chem. 2001 Apr 6;276(14):10913-20. doi: 10.1074/jbc.M010975200. Epub 2001 Jan 16.
2
Tat modifies the activity of CDK9 to phosphorylate serine 5 of the RNA polymerase II carboxyl-terminal domain during human immunodeficiency virus type 1 transcription.在1型人类免疫缺陷病毒转录过程中,Tat修饰CDK9的活性,使其对RNA聚合酶II羧基末端结构域的丝氨酸5进行磷酸化。
Mol Cell Biol. 2000 Jul;20(14):5077-86. doi: 10.1128/MCB.20.14.5077-5086.2000.
3
Cyclin C/CDK8 and cyclin H/CDK7/p36 are biochemically distinct CTD kinases.细胞周期蛋白C/周期蛋白依赖性激酶8以及细胞周期蛋白H/周期蛋白依赖性激酶7/p36是生物化学性质不同的C端结构域激酶。
Oncogene. 1999 Jan 28;18(4):1093-102. doi: 10.1038/sj.onc.1202399.
4
Comparative genomics of cyclin-dependent kinases suggest co-evolution of the RNAP II C-terminal domain and CTD-directed CDKs.细胞周期蛋白依赖性激酶的比较基因组学表明RNA聚合酶II C末端结构域和CTD导向的细胞周期蛋白依赖性激酶共同进化。
BMC Genomics. 2004 Sep 20;5:69. doi: 10.1186/1471-2164-5-69.
5
Transcriptional activity of positive transcription elongation factor b kinase in vivo requires the C-terminal domain of RNA polymerase II.体内正转录延伸因子b激酶的转录活性需要RNA聚合酶II的C末端结构域。
Gene. 2000 Aug 22;254(1-2):139-45. doi: 10.1016/s0378-1119(00)00278-x.
6
Phosphorylation of the RNA polymerase II carboxyl-terminal domain by CDK9 is directly responsible for human immunodeficiency virus type 1 Tat-activated transcriptional elongation.细胞周期蛋白依赖性激酶9对RNA聚合酶II羧基末端结构域的磷酸化直接负责1型人类免疫缺陷病毒Tat激活的转录延伸。
Mol Cell Biol. 2002 Jul;22(13):4622-37. doi: 10.1128/MCB.22.13.4622-4637.2002.
7
HIV-1 Tat-associated RNA polymerase C-terminal domain kinase, CDK2, phosphorylates CDK7 and stimulates Tat-mediated transcription.HIV-1反式激活因子相关的RNA聚合酶C末端结构域激酶CDK2使CDK7磷酸化,并刺激反式激活因子介导的转录。
Biochem J. 2002 Jun 15;364(Pt 3):649-57. doi: 10.1042/BJ20011191.
8
CDK9 autophosphorylation regulates high-affinity binding of the human immunodeficiency virus type 1 tat-P-TEFb complex to TAR RNA.细胞周期蛋白依赖性激酶9(CDK9)的自磷酸化调节人类免疫缺陷病毒1型反式激活因子-P-TEFb复合物与反式激活应答元件(TAR)RNA的高亲和力结合。
Mol Cell Biol. 2000 Sep;20(18):6958-69. doi: 10.1128/MCB.20.18.6958-6969.2000.
9
Three cyclin-dependent kinases preferentially phosphorylate different parts of the C-terminal domain of the large subunit of RNA polymerase II.三种细胞周期蛋白依赖性激酶优先磷酸化RNA聚合酶II大亚基C末端结构域的不同部分。
Eur J Biochem. 2004 Mar;271(5):1004-14. doi: 10.1111/j.1432-1033.2004.04002.x.
10
The growth factor granulin interacts with cyclin T1 and modulates P-TEFb-dependent transcription.生长因子颗粒蛋白与细胞周期蛋白T1相互作用并调节P-TEFb依赖性转录。
Mol Cell Biol. 2003 Mar;23(5):1688-702. doi: 10.1128/MCB.23.5.1688-1702.2003.

引用本文的文献

1
Cyclin-dependent protein kinases and cell cycle regulation in biology and disease.细胞周期蛋白依赖性蛋白激酶与生物学和疾病中的细胞周期调控
Signal Transduct Target Ther. 2025 Jan 13;10(1):11. doi: 10.1038/s41392-024-02080-z.
2
HIV-2 inhibits HIV-1 gene expression via two independent mechanisms during cellular co-infection.在细胞共感染过程中,HIV-2 通过两种独立的机制抑制 HIV-1 基因表达。
J Virol. 2023 Dec 21;97(12):e0187022. doi: 10.1128/jvi.01870-22. Epub 2023 Nov 22.
3
Catalytic activity of the Bin3/MePCE methyltransferase domain is dispensable for 7SK snRNP function in Drosophila melanogaster.
Bin3/MePCE 甲基转移酶结构域的催化活性对于果蝇 7SK snRNP 功能而言并非必需。
Genetics. 2024 Jan 3;226(1). doi: 10.1093/genetics/iyad203.
4
Novel covalent CDK7 inhibitor potently induces apoptosis in acute myeloid leukemia and synergizes with Venetoclax.新型共价 CDK7 抑制剂可强力诱导急性髓系白血病细胞凋亡,并与 Venetoclax 产生协同作用。
J Exp Clin Cancer Res. 2023 Jul 29;42(1):186. doi: 10.1186/s13046-023-02750-w.
5
CDK7 controls E2F- and MYC-driven proliferative and metabolic vulnerabilities in multiple myeloma.CDK7 控制多发性骨髓瘤中 E2F 和 MYC 驱动的增殖和代谢脆弱性。
Blood. 2023 Jun 8;141(23):2841-2852. doi: 10.1182/blood.2022018885.
6
Identification of CDK7 Inhibitors from Natural Sources Using Pharmacoinformatics and Molecular Dynamics Simulations.利用药物信息学和分子动力学模拟从天然来源中鉴定CDK7抑制剂
Biomedicines. 2021 Sep 10;9(9):1197. doi: 10.3390/biomedicines9091197.
7
Discovery and resistance mechanism of a selective CDK12 degrader.选择性 CDK12 降解剂的发现和耐药机制。
Nat Chem Biol. 2021 Jun;17(6):675-683. doi: 10.1038/s41589-021-00765-y. Epub 2021 Mar 22.
8
HIV-1 Proviral Transcription and Latency in the New Era.HIV-1 前病毒转录和潜伏期的新纪元。
Viruses. 2020 May 18;12(5):555. doi: 10.3390/v12050555.
9
P-TEFb as A Promising Therapeutic Target.P-TEFb 作为一种有前途的治疗靶点。
Molecules. 2020 Feb 14;25(4):838. doi: 10.3390/molecules25040838.
10
CDK7 Inhibition Suppresses Castration-Resistant Prostate Cancer through MED1 Inactivation.CDK7 抑制通过 MED1 失活抑制去势抵抗性前列腺癌。
Cancer Discov. 2019 Nov;9(11):1538-1555. doi: 10.1158/2159-8290.CD-19-0189. Epub 2019 Aug 29.